At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States

Pranay Sinha; Karen R Jacobson; C Robert Horsburgh Jr; Carlos Acuña-Villaorduña

doi:10.1093/ofid/ofad177

At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States

Open Forum Infect Dis. 2023 Apr 3;10(4):ofad177. doi: 10.1093/ofid/ofad177. eCollection 2023 Apr.

Authors

Pranay Sinha¹, Karen R Jacobson¹, C Robert Horsburgh Jr^{1

2

3

4}, Carlos Acuña-Villaorduña¹

Affiliations

¹ Section of Infectious Diseases, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
² Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA.
³ Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
⁴ Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.

Abstract

Multidrug-resistant tuberculosis (MDR-TB) has historically required longer treatment regimens that were associated with higher unfavorable outcomes and side effects rates compared with drug susceptible TB (DS-TB). During the last decade, several studies conducted mostly in high-incidence settings have shown that MDR-TB can be successfully treated using all-oral shorter regimens of 6- to 9-month duration. In this article, we review the evolution of MDR-TB treatment from the early long regimens with injectables agents (IAs), followed by the shorter regimens with IA, to the groundbreaking, all-oral, 6- to 9-month regimens. Finally, we propose a framework for implementation of the shorter all-oral regimens in the United States.

Keywords: MDR tuberculosis; all oral; treatment.

Publication types

Review